FibroGen to Present at Upcoming Investor Conferences
27 May 2020 - 9:00PM
FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique
Conterno, Chief Executive Officer, will participate in fireside
chats at the following virtual healthcare conferences:
- Jefferies 2020 Healthcare Conference on June 02 at 3:30 PM
Eastern Time; and
- Goldman Sachs 41st Annual Global Healthcare Conference on June
09 at 3:00 PM Eastern Time
A live audio webcast will be available on the “Events &
Presentations” section of the FibroGen’s Investor webpage at
https://fibrogen.gcs-web.com/. A replay will be available for
approximately 30 days.
About FibroGenFibroGen, Inc. is a biopharmaceutical company
committed to discovering, developing and commercializing a pipeline
of first-in-class therapeutics. The company applies its pioneering
expertise in hypoxia-inducible factor (HIF) and connective tissue
growth factor (CTGF) biology to advance innovative medicines to
treat unmet needs. The Company is currently developing and
commercializing roxadustat, an oral small molecule inhibitor of HIF
prolyl hydroxylase activity, for anemia associated with chronic
kidney disease (CKD). Roxadustat is also in clinical development
for anemia associated with myelodysplastic syndromes (MDS) and for
chemotherapy-induced anemia. Pamrevlumab, an anti-CTGF human
monoclonal antibody, is in clinical development for the treatment
of idiopathic pulmonary fibrosis (IPF), locally advanced
unresectable pancreatic cancer, and Duchenne muscular dystrophy
(DMD). For more information, please visit
www.fibrogen.com.
Contact: FibroGen, Inc.
Media Inquiries: Sara Iacovino 1.703.474.4452
sara.iacovino@gcihealth.com
Investors: Michael Tung, M.D. Corporate
Strategy / Investor Relations
1.415.978.1434mtung@fibrogen.com
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Apr 2024 to May 2024
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From May 2023 to May 2024